Coronavirus Dialogue Series: Medical Meetings, Post COVID-19
Date: June 17, 2020
You must be registered to participate!
1 Clock Hour | Domain A: Strategic Planning
Medical meetings have mostly cancelled, postponed or have been converted into virtual meetings in 2020 due to the Coronavirus crisis. In recent weeks, many of the our peers are undergoing significant transformations—changing how staffers communicate, adding necessary flexibility in responding and adapting to new demands for meeting formats and styles, cancelling and rescheduling contracts,—all while navigating complex compliance laws and regulations.
Who Should Attend?
- Corporate medical meeting professionals
- Healthcare medical meeting professionals
- Congress organizers
- Third-party meeting planning companies
- Procurement professionals
- Compliance professionals
- Other healthcare suppliers
- Participants will learn about updates on the status of medical meetings in the U.S and Europe.
- Partiticpants will understand changing regulations as a result of the pandemic.
- Participants will discuss virtual meetings and the rapid release of new technology.
- Participants will be able to explaing legal disclaimers and new force majeure language.
- Participants will be able to define the new HCP experience.
This Session Graciously Sponsored by:
Pat Schaumann, CMP, CSEP, DMCP, HMCC, President, Schaumann Consulting Group
Michael Verlotta, Senior Director, Medical Education, Janssen Biotech
Christian-Claus Roth, Head Scientific Engagement Governance, Novartis and Co President, IPCAA, Novartis + IPCAA
Thomas Reiser, Executive Director, International Society on Thrombosis and Haemostasis
John P. Oroho, Attorney and Principal, Porzio, Bromberg & Newman; Life Sciences Compliance and Regulatory Counseling Department
Michael Mahoney, HMCC, Senior Director: Strategic Event Services, Genentech